Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension - PubMed (original) (raw)
Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension
Marc Mejias et al. J Hepatol. 2010 Apr.
Abstract
Background & aims: Splenomegaly is a frequent hallmark of portal hypertension that, in some cases, can be very prominent and cause symptoms like abdominal pain, splenic infarction, and cytopenia. This study characterizes the pathogenetic mechanisms leading to spleen enlargement in portal hypertensive rats and focuses on mTOR pathway as a potential modulator of splenomegaly in portal hypertension.
Methods: Characterization of splenomegaly was performed by histological, hematological, immunohistochemical and Western blot analyses in rats with portal hypertension induced by portal vein ligation, and compared with sham-operated animals. The contribution of the mTOR signaling pathway to splenomegaly was determined in rats with fully developed portal hypertension and control rats by treatment with rapamycin or vehicle.
Results: Our results illustrate that splenomegaly in portal hypertensive rats arises as a consequence of the interplay of several factors, including not only spleen congestion, as traditionally thought, but also enlargement and hyperactivation of the splenic lymphoid tissue, as well as increased angiogenesis and fibrogenesis. Since mTOR signaling plays a central role in immunological processes, angiogenesis and fibrogenesis, we next determined the involvement of mTOR in splenomegaly. Interestingly, mTOR signaling was overactivated in the spleen of portal hypertensive rats, and mTOR blockade by rapamycin profoundly ameliorated splenomegaly, causing a 44% decrease in spleen size. This effect was most likely accounted for the inhibitory action of rapamycin on lymphocyte proliferation, neovascularization and fibrosis.
Conclusions: These findings shed light on the pathogenesis of splenomegaly in portal hypertension, and identify mTOR signaling as a potential target for therapeutic intervention in this disease.
Similar articles
- Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway.
Chen Y, Wang W, Wang H, Li Y, Shi M, Li H, Yan J. Chen Y, et al. PLoS One. 2016 Jan 6;11(1):e0141159. doi: 10.1371/journal.pone.0141159. eCollection 2016. PLoS One. 2016. PMID: 26734934 Free PMC article. - Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J. Fernandez M, et al. Hepatology. 2007 Oct;46(4):1208-17. doi: 10.1002/hep.21785. Hepatology. 2007. PMID: 17654489 - Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2.
Wang W, Yan J, Wang H, Shi M, Zhang M, Yang W, Peng C, Li H. Wang W, et al. PLoS One. 2014 Jan 3;9(1):e83908. doi: 10.1371/journal.pone.0083908. eCollection 2014. PLoS One. 2014. PMID: 24404143 Free PMC article. - Functional consequences of mTOR inhibition.
Sudarsanam S, Johnson DE. Sudarsanam S, et al. Curr Opin Drug Discov Devel. 2010 Jan;13(1):31-40. Curr Opin Drug Discov Devel. 2010. PMID: 20047144 Review. - Role of spleen enlargement in cirrhosis with portal hypertension.
Bolognesi M, Merkel C, Sacerdoti D, Nava V, Gatta A. Bolognesi M, et al. Dig Liver Dis. 2002 Feb;34(2):144-50. doi: 10.1016/s1590-8658(02)80246-8. Dig Liver Dis. 2002. PMID: 11926560 Review.
Cited by
- Acoustic Radiation Forced Impulse of the Liver and the Spleen, Combined with Spleen Dimension and Platelet Count in New Ratio Scores, Identifies High-Risk Esophageal Varices in Well-Compensated Cirrhotic Patients.
Vainieri AFM, Brando E, De Vincentis A, Di Pasquale G, Flagiello V, Gallo P, Barone F, Massaro Cenere T, Di Matteo E, Picardi A, Galati G; Ultrasound Research Group (URG) of Fondazione Policlinico Universitario Campus Bio-Medico of Rome. Vainieri AFM, et al. Diagnostics (Basel). 2024 Mar 25;14(7):685. doi: 10.3390/diagnostics14070685. Diagnostics (Basel). 2024. PMID: 38611598 Free PMC article. - CT perfusion imaging of the liver and the spleen can identify severe portal hypertension.
Zhu B, Wang C, Gao J, Liu H, Li N, Teng Y. Zhu B, et al. Abdom Radiol (NY). 2024 Apr;49(4):1084-1091. doi: 10.1007/s00261-024-04193-z. Epub 2024 Feb 28. Abdom Radiol (NY). 2024. PMID: 38416165 - Recent Advances in the Pathogenesis and Clinical Evaluation of Portal Hypertension in Chronic Liver Disease.
Kotani K, Kawada N. Kotani K, et al. Gut Liver. 2024 Jan 15;18(1):27-39. doi: 10.5009/gnl230072. Epub 2023 Oct 16. Gut Liver. 2024. PMID: 37842727 Free PMC article. Review. - Prognostic significance of spleen shear wave elastography and dispersion in patients with heart failure: the crucial role of cardio-splenic axis.
Misaka T, Yoshihisa A, Ichijo Y, Ishibashi S, Matsuda M, Yamadera Y, Ohara H, Sugawara Y, Anzai F, Sato Y, Abe S, Sato T, Oikawa M, Kobayashi A, Takeishi Y. Misaka T, et al. Clin Res Cardiol. 2023 Jul;112(7):942-953. doi: 10.1007/s00392-023-02183-7. Epub 2023 Mar 20. Clin Res Cardiol. 2023. PMID: 36941484 - Application of Ultrasound Elastography in Assessing Portal Hypertension.
Zhang M, Jin H, Cao J, Ren R, Jia M, Yang Y, Li X, Chen M, Li S, Huang L, Ling W. Zhang M, et al. Diagnostics (Basel). 2022 Sep 29;12(10):2373. doi: 10.3390/diagnostics12102373. Diagnostics (Basel). 2022. PMID: 36292062 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous